The FULCRUM-VT trial evaluated the clinical utility of ultra-low temperature ablation for treating ventricular tachycardia in ...
In seven patients, there were no signs of toxicity with proton-beam radioablation, clearing the way for future studies.
In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Proton beam therapy, a radiation treatment for cancer, may be effective as a treatment for refractory ventricular tachycardia ...
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced ...
The STAR-VT trial will evaluate the number of ICD or CRT-D interventions after one year post-procedure as well as the incidence of serious adverse events associated with catheter ablation within 30 ...
Medical Device Network on MSN
Adagio Medical reports positive six-month results in FULCRUM-VT trial
The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.
Ventricular tachycardia (VT) is caused by abnormal electrical circuits originating from diseased areas of the ventricular myocardium. It usually results in a rapid heartbeat, preventing effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results